查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1666188

全球體外和植入式心臟去顫器市場 - 2025 至 2033 年

Global External and Implantable Cardiac Defibrillators Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球外部和植入式心臟去顫器市場規模達到 65.8 億美元，預計到 2033 年將達到 121.6 億美元，在 2025-2033 年預測期內的複合年成長率為 7.1%。

外部和植入式心臟去顫器是一種醫療設備，旨在透過施加可控電擊來恢復正常心律，以治療危及生命的心律不整，例如心室顫動 (VF) 和室性心動過速 (VT)。植入式心臟去顫器 (ICD) 透過手術植入體內，用於持續監測和治療心律不整。它們通常用於治療因患有先天性心臟缺陷、心肌病變、心臟衰竭或有危及生命的心律不整病史等而發生心臟驟停 (SCA) 風險較高的患者。

體外去顫器是一種攜帶式、非侵入式設備，用於緊急情況下透過放置在胸部的電極墊向心臟發送電擊。這些設備通常由急救人員、緊急醫療團隊和公共場所（如機場、商場和體育場）使用，以在心臟驟停期間恢復正常心律。自動體外去顫器（AED）是最常用的體外去顫器。它們的設計非常方便用戶使用，具有內建演算法來分析心律並在必要時自動發出電擊。旁觀者只需經過最少的訓練就可以使用 AED。

外部和植入式心臟去顫器的市場需求受到醫療需求、技術進步和心血管健康意識增強等因素的共同推動。在全球範圍內，心臟病、心律不整、心臟衰竭和心臟驟停等心血管疾病（CVD）的發生率不斷上升，對體外和植入式除顫器的需求也日益增加。例如，根據美國國立衛生研究院的數據，心血管疾病（CVD）是全球最大的死亡原因。在 2021 年 2,050 萬心血管疾病相關死亡病例中，約 80% 發生在中低收入國家。

市場動態：

促進因素與約束因素

除顫器設備的技術進步

除顫器設備的技術進步正在極大地推動外部和植入式心臟去顫器市場的成長，並預計在預測期內推動市場的發展。穿戴式心臟復律去顫器，例如 Zoll Medical 的 LifeVest 和 Element Science 的 Jewel Wearable Patch 心臟復律除顫器，為患有心臟驟停 (SCA) 風險較高但尚不適合植入 ICD 的患者提供了一種非侵入性解決方案。這些穿戴式裝置可以監測心律，並在必要時自動發出電擊。

例如，2024 年 7 月，Element Science 宣布其 Jewel Wearable Patch 心律轉復除顫器（Jewel）獲得了著名的紅點設計獎。該獎項標誌著國際社會對 Jewel 獨特設計的認可，該設計注重患者的舒適度，同時提供持續的保護，避免短暫性的心臟驟停 (SCA) 風險升高，這種風險通常發生在心臟病發作等心臟事件發生後的幾週至幾個月內。

植入式心臟復律去顫器 (ICD) 和自動體外去顫器 (AED) 中電池技術的改進大大延長了這些設備的使用壽命，減少了頻繁更換的需要。就 ICD 而言，電池壽命已延長至 7-10 年，從而提高了設備的長期可行性並降低了醫療成本。

例如，美敦力 Evera MRI ICD 等設備的電池壽命延長（最長可達 10 年），透過降低患者和醫療保健提供者的整體擁有成本，促進了市場成長。它還確保設備可以使用更長時間，從而改善患者護理。

併發症和安全問題

儘管外部和植入式心臟去顫器在拯救生命方面發揮關鍵作用，但與之相關的併發症和安全問題一直是重大挑戰，減緩了市場的成長。這些問題影響患者的治療結果、臨床應用和成本效益，導致患者在開立和使用這些設備時猶豫不決。

植入式心臟復律去顫器 (ICD) 最令人擔憂的問題之一是可能產生不必要的電擊，這可能會對患者造成身心傷害。錯誤或不適當的電擊會導致患者焦慮、憂鬱並降低生活品質。例如，根據《美國心臟病學會雜誌》的一項研究，大約 13% 的 ICD 患者會出現不適當電擊，這些電擊可能會導致住院率增加、心理困擾以及對患者造成潛在傷害。

在植入式除顫器中，與設備導線（電線）或電池相關的故障可能導致設備故障，需要手術進行更換或修復。導線移位、感染或硬體故障等併發症可能需要昂貴的介入。例如，根據美國食品藥物管理局的公告，美敦力公司因高壓能量輸送持續存在問題，正在召回近35萬台植入式心臟裝置。此次召回被歸類為 I 級，即最嚴重的類型。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 依產品類型分類
  • 按患者類型分類
  • 最終用戶的程式碼片段
  • 按地區分類

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 除顫器設備的技術進步
    • 限制
      • 併發症和安全問題
    • 機會
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 5 章：外部和植入式心臟去顫器市場（按產品類型）

  • 植入式心臟復律去顫器 (ICD)
    • 經靜脈 ICD（T-ICD）
    • 皮下 ICD（S-ICD）
    • 心臟再同步治療去顫器 (CRT-Ds)
  • 體外去顫器
    • 自動體外去顫器 (AED)
    • 手動和半自動體外去顫器
    • 穿戴式心臟復律去顫器

第 6 章：外部和植入式心臟去顫器市場（按患者類型）

  • 成年人
  • 兒科

第 7 章：外部和植入式心臟去顫器市場（按最終用戶分類）

  • 醫院
  • 專科診所
  • 家庭醫療保健
  • 其他

第 8 章：外部和植入式心臟去顫器市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • Koninklijke Philips NV
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT 分析
  • Nihon Kohden Corporation
  • Medtronic plc
  • Boston Scientific Corporation
  • Stryker Corporation
  • ZOLL Medical Corporation
  • Abbott Laboratories
  • MicroPort Medical Products Ltd.
  • LivaNova PLC
  • Mindray Medical India Pvt. Ltd.

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MD9204

The global external and implantable cardiac defibrillators market reached US$ 6.58 billion in 2024 and is expected to reach US$ 12.16 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

External and implantable cardiac defibrillators are medical devices designed to treat life-threatening cardiac arrhythmias, such as ventricular fibrillation (VF) and ventricular tachycardia (VT), by delivering a controlled electric shock to restore normal heart rhythm. Implantable cardiac defibrillators (ICDs) are surgically implanted inside the body and are used for continuous monitoring and treatment of abnormal heart rhythms. They are typically prescribed to patients at high risk of sudden cardiac arrest (SCA) due to conditions like congenital heart defects, cardiomyopathy, heart failure, or a history of life-threatening arrhythmias.

External defibrillators are portable, non-invasive devices used in emergency situations to deliver an electric shock to the heart through electrode pads placed on the chest. These devices are commonly used by first responders, emergency medical teams, and public access locations (like airports, malls, and sports arenas) to restore normal heart rhythm during sudden cardiac arrest. Automated external defibrillators (AEDs) are the most commonly used external defibrillators. They are designed to be user-friendly, with built-in algorithms to analyze the heart's rhythm and automatically deliver shocks if necessary. AEDs can be used by bystanders with minimal training.

The market demand for external and implantable cardiac defibrillators is driven by a combination of medical needs, technological advancements and rising awareness about cardiovascular health. The global increase in cardiovascular diseases (CVDs) including heart attacks, arrhythmias, heart failure and sudden cardiac arrest has created a growing need for both external and implantable defibrillators. For instance, according to the National Institute of Health, cardiovascular diseases (CVDs) are the leading cause of deaths globally. Of the 20.5 million CVD-related deaths in 2021, approximately 80% occurred in low- and middle-income countries.

Market Dynamics: Drivers & Restraints

Technological Advancements in Defibrillator Devices

The rising technological advancements in defibrillator devices are significantly driving the growth of the external and implantable cardiac defibrillators market and are expected to drive the market over the forecast period. Wearable cardioverter defibrillators, such as the LifeVest by Zoll Medical and Jewel Wearable Patch Cardioverter Defibrillator by Element Science, offer a non-invasive solution for patients who are at high risk for sudden cardiac arrest (SCA) but are not yet candidates for an ICD. These wearable devices monitor heart rhythms and automatically deliver shocks when necessary.

For instance, in July 2024, Element Science announced that its Jewel Wearable Patch Cardioverter Defibrillator (Jewel) received the prestigious Red Dot Design Award. This award signals international recognition of Jewel's unique design, focusing on patient comfort while delivering continuous protection from temporary periods of elevated Sudden Cardiac Arrest (SCA) risk, which typically occurs in the weeks to months after suffering a cardiac event, such as a heart attack.

Improved battery technology in both implantable cardioverter defibrillators (ICDs) and automated external defibrillators (AEDs) has significantly extended the life of these devices, reducing the need for frequent replacements. In the case of ICDs, the battery life has been extended to 7-10 years, which improves the long-term viability of the device and reduces healthcare costs.

For instance, the extended battery life in devices like the Medtronic Evera MRI ICD (which lasts for up to 10 years) has contributed to market growth by reducing the overall cost of ownership for patients and healthcare providers. It also ensures that devices are available for longer periods, thus improving patient care.

Complications and Safety Concerns

Despite their critical role in saving lives, complications and safety concerns related to both external and implantable cardiac defibrillators have been significant challenges, slowing the growth of the market. These issues impact patient outcomes, clinical adoption and cost-effectiveness, contributing to hesitation in both prescribing and using these devices.

One of the most significant concerns with implantable cardioverter defibrillators (ICDs) is the possibility of unnecessary shocks, which can cause physical and psychological harm to patients. False or inappropriate shocks can lead to patient anxiety, depression and a diminished quality of life. For instance, according to a study in the Journal of the American College of Cardiology, inappropriate shocks occur in about 13% of ICD patients, and these shocks can lead to increased hospitalizations, psychological distress, and potential harm to the patient.

In implantable defibrillators, malfunctions related to the device's leads (wires) or battery can result in device failure, necessitating surgery for replacement or repair. Complications like lead displacement, infection, or hardware failure may require costly interventions. For instance, according to an announcement from the US Food and Drug Administration, Medtronic is recalling nearly 350,000 implantable cardiac devices due to continued problems with the delivery of high-voltage energy. The recall is categorized as a Class I, the most serious type.

Segment Analysis

The global external and implantable cardiac defibrillators market is segmented based on product type, imaging modality, application, procedure type, end-user and region.

Product Type:

The external defibrillators segment is expected to dominate the external and implantable cardiac defibrillators market share

The increasing adoption of automated external defibrillators (AEDs) in public spaces like airports, shopping malls, schools, stadiums, homes and train stations has played a pivotal role in driving the demand for external defibrillators. Public access to AEDs is essential in emergencies, providing life-saving interventions before emergency medical teams arrive. For instance, according to the National Institute of Health (NIH), sudden cardiac death from ventricular arrhythmia kills about 350,000 people annually in the United States. About 70% of sudden cardiac deaths occur at home, where an AED is usually unavailable. This further accelerates the demand for AEDs.

The introduction of next-generation AEDs has revolutionized the way defibrillators are used in emergencies. Newer models come with features like real-time data transmission, cloud connectivity, AI-powered algorithms, and improved battery life. The next-generation AEDs are more efficient and reliable, which is a key factor contributing to their dominance in the market.

For instance, in March 2024, Stryker launched a next-generation LIFEPAK CR2 automated external defibrillator (AED) for cardiac care. The LIFEPAK CR2 is a revolutionary defibrillator designed to empower rescuers to provide high-quality CPR and deliver instant shock during sudden cardiac arrest (SCA) emergencies. This innovative device incorporates QUIK-STEP electrodes which peel directly off the base for faster placement on the patient's chest and a Shock Advisory System which is an ECG analysis system that advises whether a shock is appropriate.

Geographical Analysis

North America is expected to hold a significant position in the external and implantable cardiac defibrillators market share

Cardiovascular diseases, including sudden cardiac arrest, arrhythmias and heart failure, are among the leading causes of death in North America particularly in the United States, contributing to the growing need for life-saving cardiac devices such as defibrillators. For instance, according to the Cardiac Arrest Foundation, there are more than 356,000 out-of-hospital cardiac arrests annually in the United States.

North America has extensive public education and CPR/AED training programs, increasing the number of trained individuals who are capable of using AEDs in emergency situations. This has contributed to a higher survival rate and widespread acceptance of defibrillators in both healthcare settings and public spaces.

For instance, in all, over 20 million people worldwide every year learn CPR through the American Heart Association (AHA). In the U.S., around 90% of healthcare providers have received AHA training. which has positively influenced the market by increasing the number of laypersons who can assist in life-saving procedures.

Additionally, in September 2024, the Smart Heart Sports Coalition launched the "AEDs for Youth" program, offering automated external defibrillators (AEDs) to schools and youth sports organizations at substantial discounts. In collaboration with leading AED companies Avive Solutions and Coro Medical, the program makes AEDs more accessible as students, teachers and athletes begin the new school year.

Asia-Pacific is growing at the fastest pace in the external and implantable cardiac defibrillators market

The Asia Pacific region has seen a significant increase in the prevalence of cardiovascular diseases (CVDs), which is a major driver for the demand for defibrillators. Changing lifestyles, rising levels of obesity, poor diet habits, increased smoking and sedentary behavior have contributed to the growing burden of heart diseases.

For instance, according to the World Health Organization (WHO), nearly 80% of CVD deaths occur in low- and middle-income countries in the APAC region. As per the Indian Heart Association, the annual number of deaths from CVD in India has risen from 2.26 million (1990) to 4.77 million (2020), leading to an urgent need for devices like ICDs and AEDs.

Many countries in the APAC region, particularly China, India, Japan and South Korea, have been rapidly improving their healthcare infrastructure. Governments and other private institutions have been raising awareness about the importance of defibrillators, leading to greater accessibility to advanced medical devices like implantable defibrillators (ICDs) and external defibrillators (AEDs).

For instance, in February 2024, the Udgam Group of Schools in Gujarat installed an Automated External Defibrillator (AED) in the premises of Udgam School for Children, Zebar School for Children, Satellite School for Children & Bodakdev School for Children. The initiative is part of a broader campaign to promote the usage of this life-saving technology in public spaces, particularly schools and colleges, with Udgam Group of Schools leading the way. These programs, often promoted by health organizations, government agencies, and NGOs, have significantly boosted AED usage in public places and emergencies.

Competitive Landscape

The major global players in the external and implantable cardiac defibrillators market include Koninklijke Philips N.V., Nihon Kohden Corporation, Medtronic plc, Boston Scientific Corporation, Stryker Corporation, ZOLL Medical Corporation, Abbott Laboratories, MicroPort Medical Products Ltd., LivaNova PLC, Mindray Medical India Pvt. Ltd. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global external and implantable cardiac defibrillators market report delivers a detailed analysis with 62 key tables, more than 51 visually impactful figures, and 171 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Patient Type
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Technological Advancements in Defibrillator Devices
    • 3.1.2. Restraints
      • 3.1.2.1. Complications and Safety Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. External and Implantable Cardiac Defibrillators Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Implantable Cardioverter Defibrillators (ICDs)*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Transvenous ICDs (T-ICDs)
    • 5.2.4. Subcutaneous ICDs (S-ICDs)
    • 5.2.5. Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)
  • 5.3. External Defibrillators
    • 5.3.1. Automated External Defibrillators (AEDs)
    • 5.3.2. Manual and Semi-Automatic External Defibrillators
    • 5.3.3. Wearable Cardioverter Defibrillators

6. External and Implantable Cardiac Defibrillators Market, By Patient Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 6.1.2. Market Attractiveness Index, By Patient Type
  • 6.2. Adults*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Pediatrics

7. External and Implantable Cardiac Defibrillators Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Home Healthcare
  • 7.5. Others

8. External and Implantable Cardiac Defibrillators Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Koninklijke Philips N.V.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Nihon Kohden Corporation
  • 10.3. Medtronic plc
  • 10.4. Boston Scientific Corporation
  • 10.5. Stryker Corporation
  • 10.6. ZOLL Medical Corporation
  • 10.7. Abbott Laboratories
  • 10.8. MicroPort Medical Products Ltd.
  • 10.9. LivaNova PLC
  • 10.10. Mindray Medical India Pvt. Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us